Lonza and Qurient Enter Exclusive Agreement for ADC Technology

Lonza Group AG announced an exclusive agreement with Qurient Co. Ltd. to access Qurient’s CDK7 inhibitors for dual-payload antibody-drug conjugate (ADC) applications. The partnership aims to enhance Lonza's offerings in the ADC market, enabling the integration of Qurient's inhibitors with other payloads using Lonza’s technology.

This collaboration introduces SYN-duo® CC, combining exatecan with Qurient’s CDK7 inhibitor. This new format provides ADC developers with more options for designing dual-payload ADCs, aiming to provide innovative therapeutic approaches. The agreement reflects Lonza’s strategy to expand its cutting-edge technology offerings.

Christian Seufert from Lonza stressed the significance of dual-payload ADCs in developing differentiated cancer therapies. Kiyean Nam from Qurient highlighted the potential of CDK7 inhibitors in expanding ADC applications for patients with unmet medical needs. The partnership further strengthens Lonza’s position in the evolving ADC sector.